April 29 – May 2, 2012


David Guttman

Tom Hudson

Dr. Thomas J. Hudson is President and Scientific Director of the Ontario Institute for Cancer Research (OICR), an Institute created to support multidisciplinary teams needed to effectively translate research discoveries into interventions for better prevention, detection, diagnosis and treatment of cancer. Since its inception, OICR has launched several large-scale programs including the Ontario Health Study, the One Millimetre Cancer Challenge, the Cancer Stem Cell Program, the Pancreatic Cancer Genome Project (which is part of the International Cancer Genome Consortium), the Terry Fox Research Institute/OICR Selective Therapies Program and High Impact Clinical Trials.

Dr. Hudson is internationally renowned for his work in genomics and human genome variation. Past positions include leadership roles as Director of the McGill University and Genome Quebec Innovation Centre and Assistant-Director of the Whitehead/MIT Center for Genome Research, where he led a team that generated physical and gene maps of the human and mouse genomes. Dr. Hudson has been a founding member of the International Haplotype Map Consortium, the Public Population Project in Genomics (P3G) and the International Cancer Genome Consortium. Dr. Hudson's laboratory at OICR is involved in the study of genome variation that affects cancer predisposition, progression, and response to therapy. His main project focuses on the genetic architecture of loci associated with risk to colorectal cancer.

In 2007, Dr. Hudson was appointed to the rank of Professor in the Department of Molecular Genetics at the University of Toronto. Dr. Hudson is a fellow of the Royal Society of Canada. He is editor-in-chief of the journal Human Genetics. Dr. Hudson has co-authored over 200 peer-reviewed scientific publications.

Paul Lasko

Prof. Lasko received his PhD from the Massachusetts Institute of Technology in 1986 and joined McGill in 1990 after a postdoctoral period at the University of Cambridge. Using the Drosophila system, Dr. Lasko’s research concerns regulatory processes that control gene expression at the levels of mRNA stability or translation, and that underlie germ cell or early embryonic development. He received the Award of Excellence from the Canadian Society of Genetics in 2004. At McGill he served as Chair of the Department of Biology from 2000 -2010. He assumed his position at CIHR in May 2010 but maintains his research lab at McGill.

Dr. Lasko has been highly active in research grant adjudication and served on CIHR or Canadian Cancer Society grant panels continuously since 1995. He has also worked extensively for the Human Frontiers of Science Program Organization (HFSPO) over the past ten years, serving on its program grant panel from 2001-2005, and then as one of two Canadian representatives on the Council of Scientists. He chaired the HFSP Council of Scientists since 2007-2010. Dr. Lasko also served as President of the Genetics Society of Canada from 2007-2010. As Scientific Director, Dr. Lasko oversees the Institute’s strategic research funding initiatives, many of which involve fostering international partnerships.

Xihong Lin

Dr. Lin is Professor of Biostatistics and Coordinating Director of the Program of Quantitative Genomics (PQG) at Harvard School of Public Health. Dr. Lin’s research interests lie in statistical genetics and genomics, especially development and application of statistical and computational methods for analysis of high-throughput genomic and 'omics data in population and clinical sciences, and for analysis of correlated data such as longitudinal, clustered and family data. Her statistical methodological research is currently supported by an NCI MERIT (Method to Extend Research in Time) Award entitled “Statistical Methods for Correlated and High-Dimensional Biomedical Data”. Dr. Lin’s current areas of research include analysis of sequencing association studies, rare variant effects, genome-wide association studies, genes and environment, genome-wide DNA methylation studies, risk prediction and personalized medicine.

Jean MacCluer

Alex Mackenzie

Danielle Malo

Helen McNeill

Berge Minassian

William Newman

Bill is a Clinical Senior Lecturer in Genetic Medicine at the University of Manchester, UK since 2004.

He studied Medicine at Manchester University and stayed in Manchester to complete professional training in Clinical Genetics undertaking a PhD as a Wellcome Trust Fellow on the genetics of skeletal development. He moved to Toronto to undertake a two year Fellowship with Professor Kathy Siminovitch where he worked on association studies in rheumatoid arthritis and inflammatory bowel disease. His research is now primarily focussed on pharmacogenetics, especially in cancer treatment and the role of geneticists in delivering this new clinical discipline.